Neovance

What They Do

Neovance (formerly Fortrea Patient Access, descended from Covance Market Access, est. 1996) delivers four integrated service lines under one contract:

Hub Services: Digital and traditional intake/enrollment, real-time benefits verification (AI-assisted via Infinitus voice AI partnership), prior authorization and appeals support, copay and financial assistance enrollment, prescription triage and fulfillment coordination, and omnichannel patient/provider communication. Neovance emphasizes indication-level program design — analyzing each drug-indication combination for specific payer friction points before configuring workflows, rather than applying standardized templates (Neovance).

Owned Non-Commercial Specialty Pharmacy: Neovance owns its specialty pharmacy outright (Neovance Specialty Pharmacy LLC, NPI: 1780811125, Lake Mary, FL). This is a non-commercial pharmacy purpose-built for manufacturer-sponsored programs — it handles Patient Assistance Programs (PAP), bridge/quick-start programs, replacement programs, and free-trial dispensing, but not covered-drug commercial dispensing. The facility is 40,000 sq ft, licensed in all 50 states, capable of 18,000 prescriptions daily, and dispensed 1M+ Rx in 2023 with 99% accuracy. It includes 6,000+ sq ft of cold-chain storage for biologics (Pharmaceutical Commerce, Neovance SP page).

Field Reimbursement Manager (FRM) Services: Reimbursement education for providers, local/regional policy expertise, consulting for in-house FRM teams.

Nursing Services: Personalized patient support/education, injection/device training, therapy coordination.

Competitive Positioning

Neovance occupies a Tier 1.5 “full-stack patient access specialist” position — above pure-play hub specialists (AssistRx, CareMetx) that lack owned pharmacy, but below full commercialization platforms (Eversana, Cencora) that include commercial SP, 3PL, distribution, field sales, and marketing.

vs. Eversana: Neovance’s SP is non-commercial only (PAP/free goods); Eversana offers both non-commercial and commercial specialty pharmacy plus 3PL, field sales, and marketing (Eversana Engage). Neovance positions as a deeper, indication-level-specialized patient access partner versus Eversana’s broader but potentially less specialized offering (Healthcare Tech Outlook).

vs. Valeris (formerly PharmaCord): Most analogous competitor — both are PE-backed, both offer hub + owned non-commercial SP + FRM. Valeris adds upstream market access advisory (Triangle Insights) and payer intelligence (Policy Reporter) that Neovance lacks.

vs. AssistRx/CareMetx: Neovance differentiates with owned pharmacy integration (single workflow from enrollment to dispensing) and nursing services — capabilities pure-play hub platforms don’t offer.

Recent Developments (2024-2026)

• March 2024: Fortrea signs definitive agreement to sell FPA + Endpoint Clinical to Arsenal Capital Partners for up to $345M ($295M at close + $50M milestones) (Reuters).
• June 2024: Transaction closes. Sam Osman (former Fortrea Enabling Services president) appointed Group CEO; Ray Hill (Arsenal operating partner) appointed Chairman (Arsenal Capital).
• November 2024: Neovance brand launched — “formerly Fortrea Patient Access” (LinkedIn).
• Early 2025: Steve Foran takes over as CEO (Sam Osman transitions out).
• May 2025: Infinitus AI voice BV partnership case study published — 15-30 min saved per BV case at 98% quality (Infinitus). Neovance exhibits at Asembia AXS25 Summit.
• March 2026: Named “Top Patient Access Solution 2026” by Healthcare Tech Outlook (Healthcare Tech Outlook).

Client Types & Therapeutic Focus

Serves 11 of the top 20 pharma manufacturers. Supports 1,000+ brands (lifetime), 100+ products currently, across 25+ disease areas including neurology, immunology, ophthalmology, rare diseases, hematology, oncology, cardiology, gastroenterology, rheumatology, dermatology, and diabetes (Neovance). Neovance handles 3M+ annual patient/provider interactions and has supported 2.5M+ patients. Programs are designed at the drug-indication level, suggesting mid-to-large launch clients. Conference presence at Asembia AXS Summit (booth 1807 at AXS25 and attending AXS26 in April 2026).

Technology

Neovance built a proprietary custom Customer Engagement Platform (CEP) rather than using off-the-shelf CRM (e.g., Salesforce). Developed with input from reimbursement specialists, pharmacists, nurses, and market access professionals, it includes real-time BV/PA workflow automation, case management, machine learning-driven insights, predictive analytics, and sentiment analysis. The platform is positioned as an “execution layer” — strategy drives technology, not vice versa (Neovance expertise page).

Infinitus Voice AI integration is the most notable named technology partnership: AI voice agents handle automated BV calls to payers, saving 15-30 minutes per case at 98% quality, with data flowing directly into Neovance’s CEP (Infinitus case study).

AI fraud detection in the specialty pharmacy reportedly delivers $100K+ savings per program. The platform is not publicly branded (no named equivalent to CareMetx Connect or Eversana Orchestrate).

Financial Context

Metric	Detail
Acquisition price	Up to $345M ($295M close + $50M milestones), June 2024
Revenue estimate	$100M-$500M (Seamless.AI)
Employees	1,001-5,000 (LinkedIn)
Ownership	Arsenal Capital Partners (PE, ~$10B AUM, Fund VI)
Rx dispensed (2023)	1M+ via owned non-commercial SP
Expected exit window	2028-2031 (typical Arsenal 4-7 year hold)

Notable data point: John Phelan (Trump Treasury nominee) disclosed a position in Neovance in his financial disclosure, describing the company as a “provider of post-commercialization services on behalf of pharmaceutical companies” (ProPublica).

Analyst Observations

1. The owned SP is a genuine moat — but only for non-commercial. The “enrollment to doorstep” value proposition with owned pharmacy eliminates handoff friction that pure-play hubs face. However, being non-commercial-only limits relevance for brands needing covered-drug dispensing. If Arsenal pursues a commercial SP acquisition, Neovance would become a full Tier 1 competitor.

2. Leadership churn is a yellow flag. CEO changed within the first year post-acquisition (Sam Osman out by Feb 2025, Steve Foran in). Employee reviews on Indeed noted “losing clients” and “chaotic” operations during the transition period — common post-PE-carve-out noise, but worth monitoring for client retention.

3. The 35-year heritage creates an unusual dichotomy. Neovance has deep institutional knowledge (Covance -> LabCorp -> Fortrea lineage) but is operationally a one-year-old standalone company. The rebrand, leadership change, and standalone systems buildout are still in progress. Arsenal’s $345M acquisition price implies meaningful revenue, but the transition risk is real — the company needs to prove it can retain top-20 pharma clients as an independent entity.

Sources

• Neovance Website
• Neovance Solutions
• Neovance Specialty Pharmacy
• Neovance Expertise
• Reuters - Fortrea divestiture
• Arsenal Capital Partners
• Healthcare Tech Outlook 2026
• Infinitus case study
• Pharmaceutical Commerce
• Seamless.AI
• ProPublica - Phelan disclosure
• Wave 3 research: wiki/raw/research/wave3-batch-a-hub-vendors.md